Azaindole-derivatives as factor Xa inhibitors

US7317027B2 · kind B2 · utility

Assignee

• Sanofi-Aventis Deutschland GMBH · DE

Inventors

• Marc Nazare · Idstein, DE
• Volkmar Wehner · Bischofsheim a.d.Rhön, DE
• David William Will · Schwalbach, DE
• Kurt Ritter · Heidelberg, DE
• Matthias Urmann · Eschborn, DE
• Hans Matter · Langenselbold, DE

Key dates

• Filing date: May 19, 2004
• Grant date: Jan 8, 2008
• Expiry date: May 25, 2025

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P9/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of the formula Iwherein R0, R1, R2, R3, Q, V, G and M are as defined herein. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.